Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

证券日报网讯2月13日，必贝特在互动平台回答投资者提问时表示，截至2026年2月10日，公司股东人数 为13138户。 ...

资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号 A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新 药自主研发。 2月12日，必贝特跌2.02%，成交额9104.36万元。两融数据显示，当日必贝特获融资买入额509.32万 元，融资偿还1715.01万元，融资净买入-1205.69万元。截至2月12日，必贝特融资融券余额合计1.34亿 元。 融资方面，必贝特当日融资买入509.32万元。当前融资余额1.34亿元，占流通市值的6.71%。 融券方面，必贝特2月12日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元。 截至1月30日，必贝特股东户数1.32万，较上期增加0.81%；人均流通股3532股，较上期减少0.81%。 2025年1月-9月，必贝特实现营业收入0.00元；归母净利润-1.07亿元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入 ...

关于开立募集资金现金管理专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 广州必贝特医药股份有限公司（以下简称"公司"）于2025年11月11日分别召开了第二届董事会审计委员 会2025年第五次会议、第二届董事会第七次（临时）会议、第二届监事会第七次（临时）会议，审议通 过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及公司子公司使用额度不超过 人民币9.00亿元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、满足保 本需求的理财产品或存款类产品。具体内容详见公司于2025年11月13日在上海证券交易所网站 （www.sse.com.cn）上披露的《关于使用部分暂时闲置募集资金进行现金管理的公告》（公告编号： 2025-004）。 一、开立募集资金现金管理专用结算账户情况 因募集资金现金管理的需要，公司近日在中信证券华南股份有限公司、国泰海通证券股份有限公司开立 了募集资金现金管理专用结算账户，具体信息如下： ■ 广州必贝特医药股份有限公司 4、公司财务部相关人员将及 ...

广州必贝特医药股份有限公司 证券代码：688759 证券简称：必贝特 公告编号：2026-005 关于开立募集资金现金管理专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州必贝特医药股份有限公司（以下简称"公司"）于2025年11月11日分别 召开了第二届董事会审计委员会2025年第五次会议、第二届董事会第七次（临 时）会议、第二届监事会第七次（临时）会议，审议通过了《关于使用部分暂 时闲置募集资金进行现金管理的议案》，同意公司及公司子公司使用额度不超过 人民币9.00亿元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全 性高、流动性好、满足保本需求的理财产品或存款类产品。具体内容详见公司 于2025年11月13日在上海证券交易所网站（www.sse.com.cn）上披露的《关于使 用部分暂时闲置募集资金进行现金管理的公告》（公告编号：2025-004）。 一、开立募集资金现金管理专用结算账户情况 因募集资金现金管理的需要，公司近日在中信证券华南股份有限公司、国 泰海通证券股份有限公司开立了募集 ...

（文章来源：证券日报） 证券日报网讯 2月9日，必贝特在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东人数 为13154户。 ...

Group 1 - The company has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated LDL cholesterol [1][2] - BEBT-701 is developed using the proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, aiming to provide a comprehensive management solution for high cardiovascular risk populations through a single administration that simultaneously regulates blood pressure and lipid levels [2][3] - According to the World Health Organization, approximately 1.4 billion people globally suffer from hypertension, with around 245 million adults in China affected, highlighting the significant market potential for BEBT-701 in addressing cardiovascular diseases [3]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

证券代码：688759 证券简称：必贝特 公告编号：2026-004 广州必贝特医药股份有限公司 自愿披露关于 BEBT-701 临床试验申请 获得国家药品监督管理局批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，广州必贝特医药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（NMPA）签发的《药物临床试验批准通知书》，同意公司自主研发的 全球首创AGT/PCSK9双靶点小干扰核酸（siRNA）药物BEBT-701开展用于治疗 轻中度高血压合并低密度脂蛋白胆固醇升高的I-II期临床试验。 由于药品的研发周期长、审批环节多、研发投入大，存在较多不确定性因素， 敬请广大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 一、药品基本情况 药品名称：BEBT-701 注射液 申请事项：境内生产药品注册临床试验 申请人：广州必贝特医药股份有限公司 临床试验通知书编号：2026LP00318 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 28 日受理的 BEB ...